407 related articles for article (PubMed ID: 35219307)
1. Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Broughton EI; Gooden KM; Mycock KL; Rajkovic I; Taylor-Stokes G
BMC Urol; 2022 Feb; 22(1):27. PubMed ID: 35219307
[TBL] [Abstract][Full Text] [Related]
2. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Kim HS; Seo HK
Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
4. Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists.
Moussa M; Abou Chakra M; Shore ND; Papatsoris A; Farahat Y; O'Donnell MA
Arch Ital Urol Androl; 2024 Mar; 96(1):12244. PubMed ID: 38502039
[TBL] [Abstract][Full Text] [Related]
5. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
[TBL] [Abstract][Full Text] [Related]
6. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
7. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Okajima E; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
World J Urol; 2024 Mar; 42(1):185. PubMed ID: 38512511
[TBL] [Abstract][Full Text] [Related]
9. US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guérin-Unresponsive and Bacillus Calmette-Guérin-Exposed Nonmuscle-Invasive Bladder Cancer.
Abou Chakra M; Shore ND; Dillon R; O'Donnell MA
Urol Pract; 2024 Jan; 11(1):97-107. PubMed ID: 37903746
[TBL] [Abstract][Full Text] [Related]
10. Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific.
Kikuchi E; Ng CF; Kitamura H; Ku JH; Lee LS; Lin TP; Ng JYS; Nishiyama H; Poon DM; Kanesvaran R; Seo HK; Spiteri C; Tan EM; Tsai YS; Tran B
Int J Urol; 2024 Jan; 31(1):32-38. PubMed ID: 37795933
[TBL] [Abstract][Full Text] [Related]
11. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
Noel OD; Stewart E; Cress R; Dall'Era MA; Shrestha A
Urol Oncol; 2023 Oct; 41(10):431.e7-431.e14. PubMed ID: 37295979
[TBL] [Abstract][Full Text] [Related]
12. A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guérin and Immune Checkpoint Inhibitors.
Baek SW; Leem SH
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612609
[TBL] [Abstract][Full Text] [Related]
13. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
Bedke J; Black PC; Szabados B; Guerrero-Ramos F; Shariat SF; Xylinas E; Brinkmann J; Blake-Haskins JA; Cesari R; Redorta JP
Urol Oncol; 2023 Dec; 41(12):461-475. PubMed ID: 37968169
[TBL] [Abstract][Full Text] [Related]
14. Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey.
Choo SH; Nishiyama H; Kitamura H; Chen CH; Pu YS; Lee HL; Jeong BC; Kim SI
Int J Urol; 2019 Dec; 26(12):1121-1127. PubMed ID: 31512280
[TBL] [Abstract][Full Text] [Related]
15. The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries.
Palou-Redorta J; Rouprêt M; Gallagher JR; Heap K; Corbell C; Schwartz B
World J Urol; 2014 Apr; 32(2):525-30. PubMed ID: 23907663
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC].
Loriot Y; Rouprêt M
Bull Cancer; 2020 Jun; 107(5S):S49-S55. PubMed ID: 32620207
[TBL] [Abstract][Full Text] [Related]
17. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
18. Care Quality and Variability in the Use of Intravesical Therapy for Initial Treatment of Nonmuscle Invasive Bladder Cancer Within a Large, Diverse Integrated Delivery System.
Danforth KN; Sidell MA; Luong TQ; Yi DK; Yamamoto A; Kawatkar AA; Kim PH; Loo RK; Williams SG
Urology; 2019 Sep; 131():93-103. PubMed ID: 31129191
[TBL] [Abstract][Full Text] [Related]
19. Current advances in BCG-unresponsive non-muscle invasive bladder cancer.
Tse J; Singla N; Ghandour R; Lotan Y; Margulis V
Expert Opin Investig Drugs; 2019 Sep; 28(9):757-770. PubMed ID: 31412742
[No Abstract] [Full Text] [Related]
20. New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond.
Audisio A; Buttigliero C; Delcuratolo MD; Parlagreco E; Audisio M; Ungaro A; Di Stefano RF; Di Prima L; Turco F; Tucci M
Cells; 2022 Jan; 11(3):. PubMed ID: 35159167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
